146 completed, 32 terminated, 9 withdrawn, 8 unknown. 109 Phase 2, 101 Phase 1, 9 Phase 3, 6 Not applicable, 3 Early Phase 1.
Follow temsirolimus: new trials by email Literature Review of temsirolimus trials Research Report on temsirolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee Temsirolimus, Saline placebo - Peripheral Artery Disease, Critical Limb Ischemia | Phase 3 | Recruiting | Mercator MedSystems, Inc. | 250 | 2025-07-30 | 2025-08-05 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG Temsirolimus - High Grade Glioma, Glioma | Early Phase 1 | Terminated | Nader Sanai | 5 | 2023-05-15 | 2026-05-14 |
| Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH) Sirolimus Oral Product, propranolol - Hemangioendothelioma of Liver | Phase 4 | Unknown | Shanghai Children's Medical Center | 36 | 2020-07-01 | 2020-05-29 |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Temsirolimus, Temsirolimus and dexamethasone sodium phosphate - Peripheral Arterial Disease | Phase 2 | Terminated | Mercator MedSystems, Inc. | 10 | 2019-10-01 | 2024-07-10 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
| Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors CK2 and ATM inhibitors serine/ threonin Kinase combination, Sunitinib, Pazopanib - Kidney Cancer | Not applicable | Unknown | University Hospital, Grenoble | 100 | 2017-10-16 | 2020-01-18 |
| Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) Temsirolimus, Saline - Chronic Limb Ischemia | Phase 2 | Unknown | Mercator MedSystems, Inc. | 100 | 2017-03-03 | 2020-06-11 |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 325 | 2016-06-01 | 2026-10-01 |
| Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Sunitinib, Temsirolimus, Sorafenib - Carcinoma, Renal Cell | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 4 | 2016-01-04 | 2018-10-12 |
| Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma Radiation Therapy, Temsirolimus, Vorinostat - Diffuse Intrinsic Pontine Glioma | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2015-10-05 | 2025-04-02 |
| Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 14 | 2015-10-05 | 2026-09-25 |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Temsirolimus, Etoposide, Cyclophosphamide - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 16 | 2015-07-03 | 2023-07-27 |
| Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Vinblastine, Temsirolimus - Recurrent Lymphoma, Refractory Lymphoma | Phase 1 | Completed | Canadian Cancer Trials Group | 7 | 2015-06-24 | 2023-08-04 |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) Temsirolimus, Irinotecan, Irinotecan + capecitabine - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Western Regional Medical Center | 33 | 2015-04-01 | 2018-07-02 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Cytoreductive surgery, Perifosine, Temsirolimus - Brain Tumor, Recurrent, Glioblastoma | Phase 1 | Completed | Andrew B Lassman, MD | 10 | 2014-12-08 | 2023-05-25 |
| Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting observational - Metastatic Renal Cell Carcinoma (mRCC) | Completed | Pfizer | 554 | 2014-10-31 | 2026-02-27 | |
| Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Bevacizumab, Cyclophosphamide, Valproic Acid - Solid Tumor | Early Phase 1 | Recruiting | Miller Children's & Women's Hospital Long Beach | 20 | 2014-07-01 | 2015-05-18 |
Showing 20 of 206. Sign in to see all of them.
Carcinoma, Renal Cell (27) · Glioblastoma (14) · Neoplasm Metastasis (14) · Neoplasms (13) · Prostatic Neoplasms (13) · Brain Neoplasms (11) · Breast Neoplasms (11) · Lymphoma, Mantle-Cell (11) · Endometrial Neoplasms (10) · Kidney Neoplasms (10) · Sarcoma (10) · Lymphoma, Non-Hodgkin (9) · Melanoma (9) · Gliosarcoma (8) · Glioma (7)
National Cancer Institute (NCI) (65) · M.D. Anderson Cancer Center (17) · Pfizer (12) · Washington University School of Medicine (6) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · Memorial Sloan Kettering Cancer Center (4) · Canadian Cancer Trials Group (3) · Mercator MedSystems, Inc. (3) · Puma Biotechnology, Inc. (3) · AVEO Pharmaceuticals, Inc. (2) · Central European Society for Anticancer Drug Research (2) · Charite University, Berlin, Germany (2) · City of Hope Medical Center (2) · Emory University (2) · Hellenic Cooperative Oncology Group (2)
United States (147) · Canada (31) · Germany (22) · France (17) · Australia (10) · Netherlands (10) · Spain (10) · United Kingdom (9) · Italy (8) · Poland (6) · Russia (6) · South Korea (6) · Belgium (5) · China (5) · Argentina (4)
Daniel Karp, MD (4) · Amit Oza (3) · Francis Giles (2) · Joel Picus, M.D. (2) · Kevin Kim (2) · Lillian Siu (2) · Sonali Smith (2) · Stephen Ansell (2) · Wafik T Zaky (2) · A. Craig Lockhart, M.D. (1) · Abha A Gupta (1) · Agnieszka Korfel, MD (1) · Agustin Garcia (1)
PMID 37146227, PMID 24668327, PMID 27238653, PMID 28410911, PMID 19238149, PMID 15292713, PMID 16007689, PMID 16012795, PMID 17538086, PMID 18094423, PMID 20347480, PMID 20837940, PMID 21345726, PMID 21440503, PMID 21664867, PMID 21752435, PMID 22033322, PMID 22419878, PMID 22972589, PMID 23233719, PMID 23382028, PMID 23384718, PMID 23477833, PMID 23620404, PMID 23698253, PMID 23726267, PMID 23756764, PMID 23799873, PMID 24047116, PMID 24216984, PMID 24297945, PMID 24297950, PMID 24323026, PMID 24422672, PMID 24470557, PMID 25057177, PMID 25318437, PMID 25488966, PMID 25527417, PMID 25577718, PMID 25938001, PMID 26077237, PMID 26673811, PMID 26976424, PMID 27036973, PMID 28194539, PMID 28264648, PMID 28424891, PMID 28549783, PMID 28618305
U10CA025224 (7), N01CM00071 (5), N01CM62201 (5), P30CA016672 (5), U10CA027469 (5), N01CM00038 (4), N01CM62202 (4), P30CA008748 (4), P30CA014599 (4), U10CA098543 (4), 2008 (3), N01CM00099 (3), N01CM62205 (3), N01CM62207 (3), P30CA033572 (3)